Literature DB >> 22152165

Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Donald L Patrick1, Laurie B Burke, Chad J Gwaltney, Nancy Kline Leidy, Mona L Martin, Elizabeth Molsen, Lena Ring.   

Abstract

The importance of content validity in developing patient reported outcomes (PRO) instruments is stressed by both the US Food and Drug Administration and the European Medicines Agency. Content validity is the extent to which an instrument measures the important aspects of concepts that developers or users purport it to assess. A PRO instrument measures the concepts most significant and relevant to a patient's condition and its treatment. For PRO instruments, items and domains as reflected in the scores of an instrument should be important to the target population and comprehensive with respect to patient concerns. Documentation of target population input in item generation, as well as evaluation of patient understanding through cognitive interviewing, can provide the evidence for content validity. Developing content for, and assessing respondent understanding of, newly developed PRO instruments for medical product evaluation will be discussed in this two-part ISPOR PRO Good Research Practices Task Force Report. Topics include the methods for generating items, documenting item development, coding of qualitative data from item generation, cognitive interviewing, and tracking item development through the various stages of research and preparing this tracking for submission to regulatory agencies. Part 1 covers elicitation of key concepts using qualitative focus groups and/or interviews to inform content and structure of a new PRO instrument. Part 2 covers the instrument development process, the assessment of patient understanding of the draft instrument using cognitive interviews and steps for instrument revision. The two parts are meant to be read together. They are intended to offer suggestions for good practices in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22152165     DOI: 10.1016/j.jval.2011.06.014

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  316 in total

1.  Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.

Authors:  Stefan Holmstrom; Shevani Naidoo; James Turnbull; Emily Hawryluk; Jean Paty; Robert Morlock
Journal:  Patient       Date:  2019-02       Impact factor: 3.883

2.  Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Biomarkers and surrogate endpoints in clinical trials.

Authors:  Thomas R Fleming; John H Powers
Journal:  Stat Med       Date:  2012-06-18       Impact factor: 2.373

4.  Quality of life and functional vision concerns of children with cataracts and their parents.

Authors:  Y S Castañeda; C S Cheng-Patel; D A Leske; S M Wernimont; S R Hatt; L Liebermann; E E Birch; J M Holmes
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

5.  Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study.

Authors:  Anna Rydén; Mona Martin; Katarina Halling; Anna Niklasson
Journal:  Patient       Date:  2013       Impact factor: 3.883

6.  Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.

Authors:  Heather L Gelhorn; Anne M Skalicky; Zaneta Balantac; Sonya Eremenco; Tricia Cimms; Katarina Halling; Patricia J Hollen; Richard J Gralla; Martin C Mahoney; Chris Sexton
Journal:  Support Care Cancer       Date:  2018-02-01       Impact factor: 3.603

7.  Perceptions, motivations, and concerns about living organ donation among people living with HIV.

Authors:  Sarah E Van Pilsum Rasmussen; Macey L Henderson; Juli Bollinger; Shanti Seaman; Diane Brown; Christine M Durand; Dorry L Segev; Jeremy Sugarman
Journal:  AIDS Care       Date:  2018-05-03

8.  Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale.

Authors:  Ulla Werlauff; A Højberg; R Firla-Holme; B F Steffensen; J Vissing
Journal:  Qual Life Res       Date:  2013-11-09       Impact factor: 4.147

9.  Talking About Breast Cancer: Which Symptoms and Treatment Side Effects are Important to Patients with Advanced Disease?

Authors:  Anna Niklasson; Jean Paty; Anna Rydén
Journal:  Patient       Date:  2017-12       Impact factor: 3.883

10.  Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs.

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  Patient       Date:  2019-04       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.